A High Point pharmaceutical company has received tentative approval for a potential drug intended to treat patients with relapsing forms of multiple sclerosis.
Banner Life Sciences LLC received the U.S. Food and Drug Administration approval in November, two months after the self-dismissal of a lawsuit filed by competitor Biogen Inc. Biogen said Banner's new drug Bafiertam would infringe on two patents it holds on an existing drug, Tecfidera.
